333 Changhong Dongjie, Building 3,
About Shuwen BiotechBased in China and led by U.S. diagnostic industry veterans, Shuwen Biotech is engaged in licensing and developing innovative diagnostic products and services for disease prevention, diagnosis and personalized medicine, and strives to offer in China a comprehensive menu of the most innovative diagnostic products and services for improved disease prediction, screening, diagnosis, prognosis and treatment.
CEO: Jay Z. Zhang, MS, JD
CSO: Benjamin Zhou, PhD
9 articles with Shuwen Biotech
12/10/2018Biotech and pharma companies strengthen their leadership teams with these appointments. Who made power moves in the industry this past week?
Shuwen Biotech announces its winning of an outstanding award in the national finals for the 7th Annual Innovation and Entrepreneurship organized by Chinese Ministry of Science and Technology held on November 14
Patients with advanced esophageal squamous cell carcinoma with higher PD-L1 expression can benefit better from leading PD-1 antibody drugs
Shuwen is proud to announce that it has successfully passed the 2018 biannual review and was awarded a two-year extension of the CAP accreditation.
Abcam and Shuwen Biotech Sign Strategic MoU to Establish Global Alliance for Companion Diagnostic (CDx) Kit Development
Abcam today signed a Memorandum of Understanding (MoU) with Shuwen Biotech, a leading player in the development and commercialization of companion diagnostics (CDx).
Shuwen Biotech Release: Chinese FDA Grants MammaTyper Innovative Product Status For Expedited Approval